Charactertizing Growth Hormone Deficiency in Traumatic Brain Injury
Condition(s) studied
Investigational drug(s) / intervention(s)
Not applicable (observational study): Not applicable (observational study)
Study summary
The goal of this observational study is to characterize the impact of growth hormone deficiency (GHD) on quality of life, symptom burden, and sleep in adults with traumatic brain injury (TBI), and to evaluate whether these outcomes improve with growth hormone replacement therapy.
The main questions it aims to answer are:
* Does quality of life, as measured by the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA), differ between adults with TBI and GHD compared to those with TBI and no GHD?
* Do fatigue, cognition, mood, post-concussion symptoms, body image, libido, perceived stress, and sleep architecture differ between these two groups?
* Among participants with GHD who begin growth hormone replacement therapy, do symptom burden and quality of life improve over a 12-week treatment period?
Eligible participants will be asked to complete baseline questionnaires and undergo testing for growth hormone deficiency (glucagon stimulation testing). A subset of participants will also complete objective sleep assessments using actigraphy and at-home polysomnography. For those who are diagnosed with growth hormone deficiency and choose to pursue treatment, questionnaires will be repeated bi-weekly while receiving growth hormone replacement therap
Eligibility
Primary outcome measure(s)
- Quality of Life in Adult Growth Hormone Deficiency Assessment (Qol-AGHDA) — To be completed at baseline and repeated bi-weekly during Genotropin treatment and treatment completion (3 months)
A 25-question, self-administered, condition specific quality of life measure used to determine the extent to which growth hormone deficiency has affected the patient's quality of life. Participants are instructed to answer "yes" or "no" to statements relating to problems with memory and concentration, tiredness, tenseness, social isolation and self-confidence. Higher scores indicate greater symptom burden and lower quality of life. - Glucagon Stimulation Testing — Baseline
Provocative glucagon stimulation testing completed by endocrinology. Peak growth hormone of less than 3mcg/L indicative of growth hormone deficiency
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Foothills Medical Center, Main Floor Special Services | Calgary | Alberta | Not Yet Recruiting |
| University of Calgary | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07795736 on ClinicalTrials.gov ↗ ← All trials in Canada